Potential role of UGT pharmacogenetics in cancer treatment and prevention: Focus on tamoxifen and aromatase inhibitors

Drug Metabolism Reviews

Volumn 42, Issue 1, 2010, Pages 182-194

  Lazarus, Philip ^a   Sun, Dongxiao ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Anastrazole; Aromatase inhibitors; Breast cancer; Exemestane; Glucuronidation; Metabolism; Pharmacogenetics; Tamoxifen; UDPglucuronosyltransferase

Indexed keywords

17 HYDROXYEXEMESTANE; 4 HYDROXYNORTAMOXIFEN; 4 HYDROXYTAMOXIFEN; ANASTROZOLE; AROMATASE; AROMATASE INHIBITOR; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; DRUG METABOLIZING ENZYME; ENDOXIFEN; ESTRADIOL; ESTROGEN RECEPTOR; ESTRONE; EXEMESTANE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A4; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A8; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; LETROZOLE; NORTAMOXIFEN; SULFOTRANSFERASE 1A1; TAMOXIFEN; TAMOXIFEN N OXIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BREAST CANCER; CANCER PREVENTION; CANCER RESISTANCE; DEEP VEIN THROMBOSIS; DRUG GLUCURONIDATION; DRUG METABOLISM; ENDOMETRIUM CANCER; ENZYME INHIBITION; ENZYME POLYMORPHISM; ESTROGEN SYNTHESIS; GENOTYPE; HOT FLUSH; HUMAN; LIVER MICROSOME METABOLISM; NONHUMAN; PHARMACOGENETICS; POSTMENOPAUSE; REVIEW; UTERUS CANCER; VAGINA BLEEDING; VAGINA DISCHARGE;

EID: 74549188670     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.3109/03602530903208652     Document Type: Review

References (98)

1. Anonymous. (2000). Exemestane for advanced breast cancer. Med Lett Drugs Ter 42:35-36
2. Antoniou, T., Tseng, A. L. (2005). Interactions between antiretro-virals and antineoplastic drug therapy. Clin Pharmacokinet 44:111-145.
3. Apak, T. I., Dufel, M. W. (2004). Interactions of the stereoisomers of alpha-hydroxytamoxifen with human hydroxysteroid sul-fotransferase SULT2A1 and rat hydroxysteroid sulfotransferase STa. Drug Metab Dispos 32:1501-1508.
4. AstraZeneca (2006). Arimidex anastrozole tablets. Available at: www1.astrazeneca-us.com/pi/arimidex.pdf.2006. Wilming, DE. USA. Access weblink: Jan 2007.
5. Bergman, L., Beelen, M. L., Gallee, M. P., Hollema, H., Benraadt, J., van Leeuwen, F. E. (2000). Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet 356:881-887.
6. Berkovitz, G. D., Brown, T. R., Fujimoto, M. (1987). Aromatase activity in human skin fbroblasts grown in cell culture. Steroids 50(1-3):281-295.
7. Bernstein, L., Deapen, D., Cerhan, J. R., Schwartz, S. M., Lif, J., McGann-Maloney, E., et al. (1999). Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 91:1654-1662. (Pubitemid 29479933)
8. Blevins-Primeau, A. S., Sun, D., Chen, G., Sharma, A. K., Gallagher, C. J., Amin, S., et al. (2009). Functional signifcance of UDP- glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res Epub Feb 24.
9. Boccardo, F., Rubagotti, A., Puntoni, M., Guglielmini, P., Amoroso, D., Fini, A., et al. (2005). Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 23:5138-5147.
10. Boocock, D. J., Brown, K., Gibbs, A. H., Sanchez, E., Turteltaub, K. W., White, I. N. (2002). Identifcation of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA. Carcinogenesis 23:1897-1901.
11. Borges, S., Desta, Z., Li, L., Skaar, T. C., Ward, B. A., Nguyen, A., et al. (2006). Quantitative efect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ter 80:61-74.
12. Breyer-Pfaf, U., Mey, U., Green, M. D., Tephly, T. R. (2000). Comparative N-glucuronidation kinetics of ketotifen and amitriptyline by expressed human UDP-glucuronosyltransferases and liver microsomes. Drug Metab Dispos 28:869-872.
13. Bulun, S. E., Simpson, E. R. (1994). Competitive reverse transcrip-tion-polymerase chain reaction analysis indicates that levels of aromatase cytochrome P450 transcripts in adipose tissue of buttocks, thighs, and abdomen of women increase with advancing age. J Clin Endocrinol Metab 78:428-432.
14. Buzdar, A. U., Guastalla, J. P., Nabholtz, J. M., Cuzick, J., Group, A. T. (2006). Impact of chemotherapy regimens prior to endocrine therapy: results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) Trial. Cancer 107:472-480. (Pubitemid 44107206)
15. Buzzetti, F., Di Salle, E., Longo, A., Briatico, G. (1993). Synthesis and aromatase inhibition by potential metabolites of exemes-tane (6-methylenandrosta-1,4-diene-3,17-dione). Steroids 58:527-532.
16. Chen, G., Yin, S., Maiti, S., Shao, X. (2002). 4-hydroxytamoxifen sulfa-tion metabolism. J Biochem Mol Toxicol 16:279-285.
17. Coates, A. S., Keshaviah, A., Turlimann, B., Mouridsen, H., Mauriac, L., Forbes, J. F., et al. (2007). Five years of letrozole compared with tamoxifen as initial adjuvant therapy for post-menopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25:486-492.
18. Cofman, B. L., King, C. D., Rios, G. R., Tephly, T. R. (1998). Te glu-curonidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos 26:73-77.
19. Coleman, R. E., Banks, L. M., Girgis, S. I., Kilburn, L. S., Vrdoljak, E., Fox, J., et al. (2007). Skeletal efects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised, controlled study. Lancet Oncol 8:119-127.
20. Coller, J. K. (2003). Oxidative metabolism of tamoxifen to Z-4-hydroxy-tamoxifen by cytochrome P450 isoforms: an appraisal of in vitro studies. Clin Exp Pharmacol Physiol 30:845-848.
21. Coller, J. K., Krebsfaenger, N., Klein, K., Endrizzi, K., Wolbold, R., Lang, T., et al. (2002). Te infuence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestro-gen Z-4-hydroxy-tamoxifen in human liver. Br J Clin Pharmacol 54:157-167.
22. Coombes, R. C., Kilburn, L. S., Snowdon, C. F., Paridaens, R., Coleman, R. E., Jones, S. E., et al. (2007). Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised, controlled trial. Lancet 369:559-570.
23. Crewe, H. K., Ellis, S. W., Lennard, M. S., Tucker, G. T. (1997). Variable contribution of cytochromes P450 2D6, 2C9, and 3A4 to the 4-hy-droxylation of tamoxifen by human liver microsomes. Biochem Pharmacol 53:171-178.
24. Crewe, H. K., Notley, L. M., Wunsch, R. M., Lennard, M. S., Gillam, E. M. (2002). Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy, and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos 30:869-874.
25. Cuzick, J., Powles, T., Veronesi, U., Forbes, J., Edwards, R., Ashley, S., et al. (2003). Overview of the main outcomes in breast-cancer prevention trials. Lancet 361:296-300.
26. Dehal, S. S., Kupfer, D. (1997). CYP2D6 catalyzes tamoxifen 4-hydrox-ylation in human liver. Cancer Res 57:3402-3406.
27. Desta, Z., Ward, B. A., Soukhova, N. V., Flockhart, D. A. (2004). Comprehensive evaluation of tamoxifen sequential biotrans-formation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ter 310:1062-1075.
28. Dowsett, M., Cuzick, J., Howell, A., Jackson, I. (2001). Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the Arimidex and Tamoxifen, Alone or in Combination (ATAC) Trial. Br J Cancer 85:317-324
29. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). (1998). Tamoxifen for early breast cancer: an overview of the randomised trials. Te Early Breast Cancer Trialists' Collaborative Group. (1998). Lancet 351:1451-1467
30. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). (2005). Efects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717.
31. Eisen, A., Trudeau, M., Shelley, W., Messersmith, H., Pritchard, K. I. (2008). Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review. Cancer Treat Rev 34:157-174.
32. Elahi, A., Bendaly, J., Zheng, Z., Muscat, J. E., Richie, J. P., Jr., Schantz, S. P., et al. (2003). Detection of UGT1A10 polymorphisms and their association with orolaryngeal carcinoma risk. Cancer 98:872-880.
33. Falany, C. N. (1997). Enzymology of human cytosolic sulfotrans-ferases. FASEB J 11:206-216
34. FDA. (2004). Femara. Silver Spring, Maryland, USA: U.S. Food and Drug Administration. Available at: //www.fda.gov/cder/foi/ label/2004/020726s011lbl. pdf. Access date for weblink: Feb 2007.
35. Ferretti, G., Bria, E., Giannarelli, D., Felici, A., Papaldo, P., Fabi, A., et al. (2006). Second-and third-generation aromatase inhibitors as frst-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials. Br J Cancer 94:1789-1796.
36. Fisher, B., Costantino, J. P., Redmond, C. K., Fisher, E. R., Wickerham, D. L., Cronin, W. M. (1994). Endometrial cancer in tamoxifen-treated breast cancer patients: fndings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86:527-537. (Pubitemid 24111008)
37. Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., et al. (1998). Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388.
38. Forbes, J. F., Cuzick, J., Buzdar, A., Howell, A., Tobias, J. S., Baum, M. (2008). Efect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC Trial. Lancet Oncol 9:45-53.
39. Furr, B. J., Jordan, V. C. (1984). Te pharmacology and clinical uses of tamoxifen. Pharmacol Ter 25:127-205.
40. Gallagher, C. J., Muscat, J. E., Hicks, A. N., Zheng, Y., Dyer, A. M., Chase, G. A., et al. (2007). Te UDP-glucuronosyltransferase 2B17 gene deletion polymorphism: sex-specifc association with urinary 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanol glucuronidation phenotype and risk for lung cancer. Cancer Epidemiol Biomarkers Prev 16:823-828.
41. Goetz, M. P., Kamal, A., Ames, M. M. (2008). Tamoxifen pharmacoge-nomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ter 83:160-166.
42. Goetz, M. P., Knox, S. K., Suman, V. J., Rae, J. M., Safgren, S. L., Ames, M. M., et al. (2007). Te impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101:113-121.
43. Goetz, M. P., Rae, J. M., Suman, V. J., Safgren, S. L., Ames, M. M., Visscher, D. W., et al. (2005). Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of ef-cacy and hot fashes. J Clin Oncol 23:9312-9318.
44. Green, M. D., Tephly, T. R. (1996). Glucuronidation of amines and hydroxylated xenobiotics and endobiotics catalyzed by expressed human UGT1.4 protein. Drug Metab Dispos 24:356-363.
45. Green, M. D., Tephly, T. R. (1998). Glucuronidation of amine substrates by purifed and expressed UDP-glucuronosyltransferase proteins. Drug Metab Dispos 26:860-867.
46. Howell, A., Cuzick, J., Baum, M., Buzdar, A., Dowsett, M., Forbes, J. F., et al. (2005). Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) Trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365:60-62.
47. Howell, A., Group, A. T. (2006). Analysis of fracture risk factors from the Arimadex, Tamoxifen, Alone or in Combination (ATAC) Trial: 5-year data [abstract]. J Clin Oncol 24:A563.
48. Howell, A., Howell, S. J., Evans, D. G. (2003). New approaches to the endocrine prevention and treatment of breast cancer. Cancer Chemother Pharmacol 52(Suppl 1):S39-S44.
49. Hozumi, Y., Suemasu, K., Takehara, M., Takei, H., Aihara, T., Tamura, M. (2006). Te efect of exemestane, anastrozole, and tamoxifen on the lipidemic profle of postmeonpausal early breast cancer patients: preliminary results of NSAS (National Surgical Adjusvant Study). Breast Cancer Res Treat 100:A4051.
50. Hu, Y., Dehal, S. S., Hynd, G., Jones, G. B., Kupfer, D. (2003). CYP2D6-mediated catalysis of tamoxifen aromatic hydroxylation with an NIH shift: similar hydroxylation mechanism in chicken, rat, and human liver microsomes. Xenobiotica 33:141-151.
51. Huang, Y. H., Galijatovic, A., Nguyen, N., Geske, D., Beaton, D., Green, J., et al. (2002). Identifcation and functional characterization of UDP-glucuronosyltransferases UGT1A8*1, UGT1A8*2 and UGT1A8*3. Pharmacogenetics 12:287-297.
52. Jacolot, F., Simon, I., Dreano, Y., Beaune, P., Riche, C., Berthou, F. (1991). Identifcation of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem Pharmacol 41:1911-1919.
53. Jin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K. H., et al. (2005). CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30-39.
54. Johnson, M. D., Zuo, H., Lee, K. H., Trebley, J. P., Rae, J. M., Weatherman, R. V., et al. (2004). Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85:151-159.
55. Jordan, V. C., Collins, M. M., Rowsby, L., Prestwich, G. (1977). A monohydroxylated metabolite of tamoxifen with potent antioes-trogenic activity. J Endocrinol 75:305-316.
56. Kaku, T., Ogura, K., Nishiyama, T., Ohnuma, T., Muro, K., Hiratsuka, A. (2004). Quaternary ammonium-linked glu-curonidation of tamoxifen by human liver microsomes and UDP-glucuronosyltransferase 1A4. Biochem Pharmacol 67:2093-2102.
57. Katzenellenbogen, B. S., Norman, M. J., Eckert, R. L., Peltz, S. W., Mangel, W. F. (1984). Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells. Cancer Res 44:112-119.
58. Kim, S. Y., Suzuki, N., Santosh Laxmi, Y. R., Rieger, R., Shibutani, S. (2003). Alpha-hydroxylation of tamoxifen and toremifene by human and rat cytochrome P450 3A subfamily enzymes. Chem Res Toxicol 16:1138-1144.
59. Lazarus, P., Blevins-Primeau, A. S., Zheng, Y., Sun, D. (2009). Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen. Ann N Y Acad Sci 1155:99-111.
60. Lien, E. A., Solheim, E., Kvinnsland, S., Ueland, P. M. (1988). Identifcation of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res 48:2304-2308.
61. Lien, E. A., Solheim, E., Lea, O. A., Lundgren, S., Kvinnsland, S., Ueland, P. M. (1989). Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fuids during tamoxifen treatment. Cancer Res 49:2175-2183.
62. Lim, L., Desta, Z., Rae, J., Flockhart, D., Skaar, T. (2004). Gene expression profles of 4-hydroxy-N-desmethyltamoxifen (endoxifen) and 4-hydroxytamoxifen (4OHTAM) treated human breast cancer cells determined by cDNA microarray analysis. Clin Pharmacol Ter 75:49.
63. Lim, Y. C., Desta, Z., Flockhart, D. A., Skaar, T. C. (2005). Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has antiestrogenic efects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 55:471-478.
64. Lonning, P. E., Lien, E. A., Lundgren, S., Kvinnsland, S. (1992). Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clin Pharmacokinet 22:327-358.
65. Mareck, U., Geyer, H., Guddat, S., Haenelt, N., Koch, A., Kohler, M., et al. (2006). Identifcation of the aromatase inhibitors anas-trozole and exemestane in human urine using liquid chroma-tography/tandem mass spectrometry. Rapid Commun Mass Spectrom 20:1954-1962.
66. Markopoulos, C., Polychronis, A., Zobolas, V., Xepapadakis, G., Papadiamantis, J., Koukouras, D., et al. (2005). Te efect of exemestane on the lipidemic profle of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek substudy. Breast Cancer Res Treat 93:61-66.
67. Matsumine, H., Hirato, K., Yanaihara, T., Tamada, T., Yoshida, M. (1986). Aromatization by skeletal muscle. J Clin Endocrinol Metab 63:717-720.
68. McCarroll, S. A., Hadnott, T. N., Perry, G. H., Sabeti, P. C., Zody, M. C., Barrett, J. C., et al. (2006). Common deletion polymorphisms in the human genome. Nat Genet 38:86-92.
69. McDonald, C. C., Stewart, H. J. (1991). Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. Te Scottish Breast Cancer Committee. BMJ 303:435-437.
70. Means, G. D., Kilgore, M. W., Mahendroo, M. S., Mendelson, C. R., Simpson, E. R. (1991). Tissue-specifc promoters regulate aro-matase cytochrome P450 gene expression in human ovary and fetal tissues. Mol Endocrinol 5:2005-2013.
71. Meier, C. R., Jick, H. (1998). Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol 45:608-612.
72. Murata, M., Warren, E. H., Riddell, S. R. (2003). A human minor his-tocompatibility antigen resulting from diferential expression due to a gene deletion. J Exp Med 197:1279-1289.
73. Nakamura, A., Nakajima, M., Yamanaka, H., Fujiwara, R., Yokoi, T. (2008). Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos 36:1461-1464.
74. Nelson, L. R., Bulun, S. E. (2001). Estrogen production and action. J Am Acad Dermatol 45(3 Suppl):S116-S124.
75. Nishiyama, T., Ogura, K., Nakano, H., Ohnuma, T., Kaku, T., Hiratsuka, A., et al. (2002). Reverse geometrical selectivity in glucuronidation and sulfation of cis-and trans-4-hydroxyta-moxifens by human liver UDP-glucuronosyltransferases and sulfotransferases. Biochem Pharmacol 63:1817-1830.
76. Osborne, C. K. (1998). Tamoxifen in the treatment of breast cancer. NEJM 339:1609-1618
77. Pfzer. (2007). Aromasin exemestane tablets. Available at: www.pfzer. com/fles/products/uspi-aromasin.pdf. NY, NY, USA. Access date: Oct, 2007.
78. Perez, E. A., Josse, R. G., Pritchard, K. I., Ingle, J. N., Martino, S., Findlay, B. P., et al. (2006). Efect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 24:3629-3635.
79. Poon, G. K., Chui, Y. C., McCague, R., Llnning, P. E., Feng, R., Rowlands, M. G., et al. (1993). Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients. Drug Metab Dispos 21:1119-1124.
80. Ren, Q., Murphy, S. E., Zheng, Z., Lazarus, P. (2000). O-glucuronidation of the lung carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL), by human UDP-glucuronosyltransferases 2B7 and 1A9. Drug Metab Dispos 28:1352-1360.
81. Roselli, C. E., Horton, L. E., Resko, J. A. (1985). Distribution and regulation of aromatase activity in the rat hypothalamus and limbic system. Endocrinology 117:2471-2477.
82. Rutqvist, L. E., Johansson, H., Signomklao, T., Johansson, U., Fornander, T., Wilking, N. (1995). Adjuvant tamoxifen therapy for early-stage breast cancer and second primary malignancies. Te Stockholm Breast Cancer Study Group. J Natl Cancer Inst 87:645-651.
83. Rutqvist, L. E., Mattsson, A. (1993). Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. Te Stockholm Breast Cancer Study Group. J Natl Cancer Inst 85:1398-1406.
84. Shozu, M., Simpson, E. R. (1998). Aromatase expression of human osteoblast-like cells. Mol Cell Endocrinol 139(1-2):117-129.
85. Siouf, A., Gauducheau, N., Pineau, V., Marfl, F., Jaouen, A., Cardot, J. M., et al. (1997). Absolute bioavailability of letrozole in healthy postmenopausal women. Biopharm Drug Dispos 18:779-789.
86. Stearns, V., Johnson, M. D., Rae, J. M., Morocho, A., Novielli, A., Bhargava, P., et al. (2003). Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758-1764.
87. Strassburg, C. P., Strassburg, A., Nguyen, N., Li, Q., Manns, M. P., Tukey, R. H. (1999). Regulation and function of family 1 and family 2 UDP-glucuronosyltransferase genes (UGT1A, UGT2B) in human oesophagus. Biochem J 338(Pt 2):489-498.
88. Sun, D., Chen, G., Dellinger, R. W., Duncan, K., Fang, J. L., Lazarus, P. (2006). Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants. Breast Cancer Res 8:R50.
89. Sun, D., Sharma, A. K., Dellinger, R. W., Blevins-Primeau, A. S., Balliet, R. M., Chen, G., et al. (2007). Glucuronidation of active tamoxifen metabolites by the human UDP-glucuronosyltransferases. Drug Metab Dispos 35:2006-2014. (Pubitemid 350010805)
90. Turlimann, B., Keshaviah, A., Coates, A. S., Mouridsen, H., Mauriac, L., Forbes, J. F., et al. (2005). A comparison of letro-zole and tamoxifen in postmenopausal women with early breast cancer. NEJM 353:2747-2757. (Pubitemid 43016814)
91. Tsai-Morris, C. H., Aquilano, D. R., Dufau, M. L. (1985). Cellular localization of rat testicular aromatase activity during development. Endocrinology 116:38-46.
92. Turgeon, D., Carrier, J. S., Levesque, E., Hum, D. W., Belanger, A. (2001). Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology 142:778-787.
93. van Leeuwen, F. E., Benraadt, J., Coebergh, J. W., Kiemeney, L. A., Gimbrere, C. H., Otter, R., et al. (1994). Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343:448-452.
94. Wiener, D., Doerge, D. R., Fang, J. L., Upadhyaya, P., Lazarus, P. (2004a). Characterization of N-glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) in human liver: importance of UDP-glucuronosyltransferase 1A4. Drug Metab Dispos 32:72-79.
95. Wiener, D., Fang, J. L., Dossett, N., Lazarus, P. (2004b). Correlation between UDP-glucuronosyltransferase genotypes and 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanone glucuronidation phenotype in human liver microsomes. Cancer Res 64:1190-1196.
96. Wilson, W., 3rd, Pardo-Manuel de Villena, F., Lyn-Cook, B. D., Chatterjee, P. K., Bell, T. A., Detwiler, D. A., et al. (2004). Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15. Genomics 84:707-714.
97. Zheng, Y., Sun, D., Sharma, A. K., Chen, G., Amin, S., Lazarus, P. (2007). Elimination of antiestrogenic efects of active tamoxifen metabolites by glucuronidation. Drug Metab Dispos 35:1942-1948. (Pubitemid 47481590)
98. Zheng, Z., Fang, J. L., Lazarus, P. (2002). Glucuronidation: an important mechanism for detoxifcation of benzo[a]pyrene metabolites in aerodigestive tract tissues. Drug Metab Dispos 30:397-403